TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05803785: A Phase 1, Open Label, Ascending Dose Study to Evaluate the Safety of BBC1501 Administered by Intravitreal Injection for Neovascular Age-Related Macular Degeneration (nAMD)

Sponsor: Benobio Co., Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$248,336

Rescue Site Savings

+$158,032

Unlock Full NCT05803785 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05803785 Rescue Dossier →